High flow nasal cannula for prevention of intubation in acute non-hypercapnic hypoxemic respiratory failure in immunocompromised patients, a randomized controlled trial

ประโยชน์ของออกซิเจนอัตราไหลสูงในผู้ป่วยภูมิคุ้มกันบกพร่องที่ขาดออกซิเจน

Authors

  • Juthamas Inchai Div.Pulmonary, Critical care and allergy Dept. Internal Medicine, Faculty of Medicine, Chiang Mai university
  • ปัทมพร แสงแก้ว หน่วยวิชาโรคระบบการหายใจ เวชบำบัดวิกฤตและภูมิแพ้ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
  • พนิดา ชนะญาติ หน่วยวิชาโรคระบบการหายใจ เวชบำบัดวิกฤตและภูมิแพ้ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่
  • เฉลิม ลิ่วศรีสกุล หน่วยวิชาโรคระบบการหายใจ เวชบำบัดวิกฤตและภูมิแพ้ ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่

Keywords:

ออกซิเจนอัตราไหลสูงผ่านทางจมูก, เครื่องช่วยหายใจชนิดไม่ใส่ท่อช่วยหายใจ, ระบบหายใจล้มเหลวจากการขาดออกซิเจน, ผู้ป่วยภูมิคุ้มกันบกพร่อง

Abstract

Objectives  To compare the outcomes of high flow nasal cannula (HFNC) with non-invasive ventilation (NIV) for treatment of acute non-hypercapnic hypoxemic respiratory failure in immunocompromised patients.

Methods  Immunocompromised patients with acute hypoxemic respiratory failure (AHRF) admitted to our university hospital were randomized 1:1 to receive either HFNC or NIV treatment in medical ICU. The primary outcome was the need for intubation and IMV within 48 hours after randomization. Secondary outcomes included ICU, 30-day and hospital mortality.

Results During the study period, 19 patients were randomized. Baseline mean respiratory rate was 28.1±4.4/min vs 27.2±5.9 /min and mean P/F ratio was 197.8±66.1 vs 204.5±44.5 in the HFNC and NIV groups, respectively.  Median SOFA score was 5 (IQR,3-7) vs 3.5 (IQR,2.75-5.75) and median SAPS II score was 26 in both groups. Causes of AHRF were 61.5% infection and 38.5% non-infection. The need for intubation and IMV within 48 hours after randomization was not significantly different between groups (33.3% vs 20.0%, p = 0.51). Mortality on day 30 was 55.6% vs 40%, p = 0.64). No significant difference was observed in ICU length of stay (2 vs 5.5 days; p = 0.168) or hospital length of stay (18 vs 21 days; p = 0.836).

Conclusion  Among immunocompromised patients with acute hypoxemic respiratory failure, HFNC did not significantly decrease intubation rate at 48 hour compared with NIV.

Downloads

Download data is not yet available.

References

Wang T, Zhang L, Luo K, He J, Ma Y, Li Z, et al. Noninvasive versus invasive mechanical ventilation for immunocompromised patients with acute respiratory failure: a systematic review and meta-analysis. BMC Pulm Med. 2016;16:129.

Huang H-B, Xu B, Liu G-Y, Lin J-D, Du B. Use of noninvasive ventilation inimmunocompromised patients withacute respiratory failure: a systematicreview and meta-analysis. Crit Care. 2017;21:4.

Keenan SP, Sinuff T, Burns KEA, Muscedere J, Kutsogiannis S, Mehta S, et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive conti-nuous positive airway pressure in the acute care setting. CMAJ. 2011;183: E195-E214.

Rochwerg B,Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017; 50:1602426.

Parke RL, Eccleston ML, McGuinness SP. The effects of flow on airway pressure during nasal high-flow oxygen therapy. Respir Care. 2011;56:1151-5.

Vargas F, Saint-Leger M, Boyer A, Bui NH, Hilbert G. Physiologic effects of high-flow nasal cannula oxygen in critical care subjects. Respir Care. 2015;60:1369-76.

Spoletini G, Alotaibi M, Blasi F, Hill NS. Heated humidified high-flow nasal oxygen in adults: Mechanisms of action and clinical implications. Chest. 2015;148:253-261.

Mauri T, Turrini C, Eronia G, Volta CA, Bellani G, et al. Physiologic effects of high-flow nasal cannula in acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2017;195:1207-15.

Coudroy R, Jamet A, Petua P, Robert R, Frat J-P, Thille AW. High flow nasal cannula oxygentherapy versus noninvasive ventilationin immunocompromised patients with acute respiratory failure: an observational cohort study. Ann Intensive Care. 2016;6:45.

Frat J-P, Ragot S, Girault C, Perbet S, Prat G, Boulain T, et al. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial. Lancet Respir Med. 2016;4:646-52.

Huang HB, Peng JM, Weng L, Weng L, Liu GY, Du B. High-flow oxygen therapy in immunocompromised patients with acute respiratory failure: A review and meta-analysis. J Crit Care. 2018;43:300-5.

Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372:2185-96.

Published

2020-12-28

How to Cite

1.
Inchai J, แสงแก้ว ป, ชนะญาติ พ, ลิ่วศรีสกุล เ. High flow nasal cannula for prevention of intubation in acute non-hypercapnic hypoxemic respiratory failure in immunocompromised patients, a randomized controlled trial : ประโยชน์ของออกซิเจนอัตราไหลสูงในผู้ป่วยภูมิคุ้มกันบกพร่องที่ขาดออกซิเจน. Chiang Mai Med J. [Internet]. 2020 Dec. 28 [cited 2022 Jun. 29];59(3):127-36. Available from: https://he01.tci-thaijo.org/index.php/CMMJ-MedCMJ/article/view/239950

Issue

Section

Original Article